Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorFidan, Aykut Kursat
dc.contributor.authorUcmak, Gulin
dc.contributor.authorDemirel, Bedriye Busra
dc.contributor.authorEfeturk, Hulya
dc.contributor.authorOzturk, Ipek
dc.contributor.authorDemirtas Senlik, Semra
dc.contributor.authorErgurhan Ilhan, Inci
dc.date.accessioned2021-11-01T15:05:43Z
dc.date.available2021-11-01T15:05:43Z
dc.date.issued2021
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.urihttps://doi.org/10.3906/sag-2004-358
dc.identifier.urihttps://hdl.handle.net/11491/7378
dc.description.abstractBackground/aim: The aim of this study was to investigate the contribution of fluorine-18 (F-18) fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) imaging in staging of pediatric osteosarcoma patients and also to evaluate the ability of metabolic parameters from the primary tumor to predict tumor necrosis rate (TNR). Material and methods: F-18 FDG-PET/CT imaging was performed in staging 37 pediatric osteosarcoma patients. The metabolic parameters SUVmax (maximum standardised uptake value), MTV (metabolic tumour volume), and TLG (total lesion glycolysis) were measured from the primary tumor. TNR level of the primary tumor was histopathologically measured after standard neoadjuvant chemotherapy treatment. The contribution of F-18 FDG-PET/CT to staging of pediatric osteosarcoma patients and the accuracy of metabolic parameters of the primary tumor to predict TNR were analized by regression analysis. Results: MTV and TLG of the primary tumor were found to efficiently predict histopathologic TNR, whereas SUVmax was not (P = 0.012, P = 0.027, P = 0.25, respectively). Also 5 of 12 patients (41.6%) who were initially defined as localised osteosarcoma were upstaged in consequence of staging F-18 FDG-PET/CT findings. Conclusion: F-18 FDG-PET/CT staging in pediatric osteosarcoma patients can effectively distinguish metastatic-localised disease. MTV and TLG values are important parameters, which can efficiently be used to predict TNR.en_US
dc.language.isoengen_US
dc.publisherTubitak Scientific & Technical Research Council Turkeyen_US
dc.relation.ispartofTurkish Journal Of Medical Sciencesen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPediatric osteosarcomaen_US
dc.subjectpositron emission tomographyen_US
dc.subjecttumor necrosis rateen_US
dc.subjectaykutkursat@gmailen_US
dc.subjectcomen_US
dc.titleThe relation between staging fluorine-18 fluorodeoxyglucose positron emission tomog-raphy/computed tomography metabolic parameters and tumor necrosis rate in pediatric osteosarcoma patientsen_US
dc.typearticleen_US
dc.department[Belirlenecek]en_US
dc.identifier.volume51en_US
dc.identifier.issue3en_US
dc.identifier.startpage1115en_US
dc.identifier.endpage1122en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.department-temp[Fidan, Aykut Kursat] Hitit Univ, Dept Nucl Med, Corum Erol Olcok Educ & Training Hosp, Corum, Turkey; [Ucmak, Gulin; Demirel, Bedriye Busra; Efeturk, Hulya; Demirtas Senlik, Semra] Univ Hlth Sci, Dept Nucl Med, Dr Abdurrahman Yurtaslan Ankara Oncol Educ & Trai, Ankara, Turkey; [Ozturk, Ipek] Mehmet Akif Inan Res & Training Hosp, Dept Nucl Med, Sanliurfa, Turkey; [Akkas, Burcu Esen] Univ Hlth Sci, Dept Nucl Med, Sultan Abdulhamid Han Educ & Training Hosp, Istanbul, Turkey; [Ergurhan Ilhan, Inci] Univ Hlth Sci, Dr Abdurrahman Yurtaslan Ankara Oncol Educ & Trai, Dept Pediat Hematol Oncol, Ankara, Turkeyen_US
dc.contributor.institutionauthor[Belirlenecek]
dc.identifier.doi10.3906/sag-2004-358
dc.description.wospublicationidWOS:000668244900026en_US
dc.description.scopuspublicationid2-s2.0-85109991916en_US
dc.description.pubmedpublicationidPubMed: 33387988en_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster